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The Division of Insurance ("Division") issues this Bulletin to update Bulletin 2020-02 regarding 
COVID-19 testing and to provide infonnation to Commercial Health Insurers, Blue Cross and Blue 
Shield of Massachusetts, Inc., and Health Maintenance Organizations ("Carriers") about the 
Division's expectations regarding Carriers' coverage for COVID-19, also known as Coronavirus. 
Recognizing that members of the public may seek a variety of laboratory tests for SARS-Co V-2 or 
the novel Coronavirus, the virus that causes COVID-19,. this Bulletin addresses coverage for 
COVID-19 testing that is medically necessary to diagnose or treat Coronavirus or other covered 
health conditions. 
The Coronavirus Risk 
The public health, economic and societal consequences of the spread of the Coronavirus have 
dramatic impacts in the Commonwealth. It is essential that government and business leaders take 
all appropriate steps to safeguard the general public and well-being of the Commonwealth's citizens. 
Health insurance coverage plays a critical role in the public's actual and perceived access to and 
affordability of health care services. Coronavirus may impose unique risks to our insurance market 
that Massachusetts has not faced for at least a generation. Therefore, the Division is notifying 
Massachusetts Carriers that it expects them to take all necessary steps to enable their covered 
members to obtain medically necessary and appropriate testing and treatment that will help fight the 
spread of this disease. 
As noted in Bulletin 2020-02, the Division expects Carriers to communicate prevention, testing and 
treatment options to covered persons in accordance with guidelines from the Massachusetts 
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Department of Public Health ("DPH") and the Centers for Disease Control and Prevention ("CDC"). 
The Division also noted that as the situation evolved, the Division would issue further clarifying 
bulletins. 
Please note that the Division expects that Carriers do the following regarding testing: 
• Establish dedicated help lines to respond to all calls about the Coronavirus and keep covered 
members aware of providers who test/treat the virus, members' available benefits, and 
phone numbers that members can call for additional help. 
• Relax prior approval requirements and procedures so th'at members can get timely medically 
necessary treatment, in accordance with DPH and CDC guidelines, if they are at risk of 
contracting the Coronavirus. 
• Eliminate prior approval requirements for antigen and polymerase chain reaction ("PCR") 
testing for COVID-19, in accordance with DPH and CDC guidelines. 
• Relax out-of-network requirements and procedures when access to testing or urgent 
treatment, in accordance with DPH and CDC requirements, is unavailable from in-network 
providers. 
• Forego any cost-sharing (copayments, deductibles, or coinsurance) for medically necessary 
Coronavirus testing, counseling and vaccinations at in-network doctors' offices, urgent care 
centers, or emergency rooms; and at out-of-network doctors' offices, urgent care centers, or 
emergency rooms when access to testing or urgent treatment, in accordance with DPH and 
CDC requirements, is unavailable from in-network providers. 
COVID-19 PCR, Antigen and Antibody Testing 
At present, the Divjsion is aware that there are three types of COVID-19 tests. 
• PCR tests look for the presence of the unique RNA of the novel Coronavirus in a patient. 
• Antigen tests look for a unique part of the novel Coronavirus, such as a specific protein on 
one of the unique novel Corona virus spikes. 
• Antibody tests (also known as serology tests) look for presence of antibodies in a patient's 
immune system that may fight off the novel Coronavirus. 
Please be aware that the Division expects Carriers to cover PCR or antigen tests desi~ned to detect 
the presence of the novel Coronavirus when a covered patient has any symptom of COVID-19 or 
the patient has been exposed to COVID-19. The Division expects that specimen collection and lab 
processing costs associated with COVID-19 shall be reimbursed at a rate greater than the 
MassHealth rate when individually reimbursed. Carriers' applicable specimen collection and lab 
processing practices shall otherwise apply. 
Regarding antibody tests, the Division expects Carriers to cover antibody tests for a covered patient 
when such tests are being conducted consistent with DPH and CDC guidance and are medically 
necessary in order to support treatment for COVID-19 or for treatment of another disease. 
Developing Coronavirus Testing Medical Necessity Guidelines 
Pursuant to M.G.L. c. 1760, §16(b), Massachusetts-issued insured health plans are required to 
provide coverage for health care services if (l) the services are a covered benefit under the insured's 
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health benefit plan; and (2) the services are medically necessary. Insured health plans that are 
accredited by the Division as managed care companies under M.G.L. c. 1760 may employ utilization 
review systems in making decisions about whether services are medically necessary. Utilization 
review is defined in M.G.L. c. 1760 as "a set of formal techniques designed to monitor the use of, 
or evaluate the clinical necessity, appropriateness, efficacy, or efficiency of, health care services, 
procedures or settings." Carriers should review all relevant medical necessity criteria and develop 
appropriate criteria for use in determining the medical necessity of all cases. 
Carriers may develop utilization review systems that apply to COVID-19 tests, provided that they 
are consistent with the provisions of M.G.L. c. 1760. Carriers may establish systems that evaluate 
the clinical necessity, appropriateness, efficacy, or efficiency of, health care services, procedures or 
settings through ambulatory review, prospective review, second opinion, certification, concurrent 
review, case management, discharge planning, or retrospective review, provided that such systems · 
comply with the requirements of M.G.L. c. 1760, §12 and 211 CMR 52.00. In addition, Carriers 
may require that a test be ordered by a treating physician based on health plan medical necessity 
criteria. Carriers that establish medical necessity criteria for COVID-19 testing should explain 
relevant testing provisions and procedures to members and all network providers so that they are 
aware of the requirements before members begin receiving health services. 
As required under M.G.L. c. ·1760, §16(c), "[a]ny such medical necessity guidelines criteria shall 
be applied consistently by a [C]arrier or a utilization review organization and made easily accessible 
and up-to-date on a [C]arrier or utilization review organization's.website to insureds, prospective 
insureds and health care providers consistent with subsection (a) of section 12. If a [C]arrier or 
utilization review organization intends either to implement a new medical necessity guideline or 
amend an existing requirement or restriction, the [C]arrier or utilization review organization shall 
ensure that the new or amended requirement or restriction shall not be implemented unless the 
[C]arrier's or utilization review organization's website has been updated to reflect the new or 
amended requirement or restriction." If a Carrier adopts new medical necessity guidelines associated 
with any COVID-19-related test, it should make these policies clear to all contracting providers, as 
well as covered employees and members in order to delineate when the Carrier will cover and pay · 
for Coronavirus testing. 
Carriers Acting As Administrators 
Due to the public health crisis caused by Coronavirus, when Carriers are acting as administrators for 
employment-sponsored non-insured health benefit plans, the Division expects Carriers to encourage 
plan sponsors to take steps that are consistent with the provisions of Bulletins 2020-02, 2020-04, 
2020-10, 2020-15 and 2020-16. Plan sponsors should be made aware of the public health risks to 
all Massachusetts residents, and Carriers should do all they can to encourage plan sponsors to take 
steps to remove barriers to accessing medically necessary testing, diagnosis, counseling, and 
treatment of Coronav1rus. 
If you have any questions about this Bulletin, please contact Kevin Beagan, Deputy Commissioner 
for the Health Care Access Bureau, at ( 617) 521-7323. 
